ABSTRACT

Alzheimer's disease (AD) is a chronic neurological condition that primarily affects elderly people and gradually impairs memory and other cognitive abilities. It is characterized by aggregation of senile plaques, hyper phosphorylated tau protein, irreversible loss of neurons and synaptic insufficiency. It has been founded that Wnt Signalling inhibition can hasten the onset and progression of AD neuropathology and memory loss. So Wnt signaling is a well- known system that plays important functions in controlling neural development, synaptic transmission, and plasticity. As Wnt modulators Wnt proteins, Oxoglutarate dehydrogenase- like (OGDHL), certain statins like simvastatin, and some naturally occurring compounds such as curcumin, cannabidiol, and ginkolide b are examples of medications that have recently exhibited Wnt/?-targeting activity. Emerging evidences suggests that sigma 1 receptor agonists like fluoxetine and citalopram may also be effective novel therapeutics for the treatment of Alzheimer's disease. This review summarizes the contribution of the Wnt signaling system to AD pathogenesis by focusing on the possible therapeutic implications of Wnt modulators in brain synaptic remodeling. Keywords: Alzheimer’s disease, A? precursor protein, Sigma 1 receptor, Synaptic remodeling
Publication date: 01/12/2023

https://ijbpas.com/pdf/2023/December/MS_IJBPAS_2023_7538.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.12.7538